New combo aims to wipe out rare bladder cancer before surgery

NCT ID NCT06091124

Recruiting now Disease control Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether giving a combination of adebrelimab (an immunotherapy) plus chemotherapy before bladder removal surgery can completely eliminate neuroendocrine bladder cancer in 22 adults. Participants will receive up to 4 cycles of the drug combo before surgery. The main goals are to see how many patients have no cancer left at surgery and to check the treatment's safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

urinary bladder carcinoma Urinary Bladder Neoplasms urinary bladder small cell neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER NEUROENDOCRINE CARCINOMA OF THE BLADDER

Contacts and locations

Locations

Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, China
RenJi Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200127, China
The First Affiliated Hospital of Xi'an Jiao Tong University
RECRUITING

Xi'an, Shaanxi, China
The Second Hospital of Tianjin Medical University
RECRUITING

Tianjin, Tianjin Municipality, China
West China Hospital
RECRUITING

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.